immatics is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product can50 didates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 â€“ and thus less than three years after the conclusion of the first round of funding totaling â‚¬14 million â€“ the company successfully concluded an international clinical study on its product candidate IMA901 for combating renal cancer. Further product candidates, also consisting of peptide-based immuno55 therapeutic substances for cancer therapy, are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline.
Funding Rounds (5) - $176.5MUpdate
Wellington Partners is a venture capital firm that invests in technology and life sciences...
National Technology Enterprises Company
KfW Bankengruppe gives impetus to economic, social and ecological development worldwide. As a...
3i is a British private equity group that has billions under management. For over 65 years...
- 07/16/14 -prnewswire.com